Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9279114 | 0.86 | KDM4E (0.44) | PDE4BKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL18816905 | 0.85 | RAB9A (0.53) | KDM4EMAPTALDH1A1KMT2AHPGD | |
| SCHEMBL1290672 | 0.79 | KDM4E (0.41) | NR4A2KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL23888976 | 0.78 | PLAT (0.49) | NR4A2KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL25367327 | 0.78 | CYP11B2 (0.47) | NR4A2KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL21893906 | 0.75 | PDE4B (0.33) | PDE4BMAPTKMT2AMEN1NPC1 | |
| SCHEMBL1863799 | 0.73 | NPC1 (0.58) | KDM4EMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL15232211 | 0.73 | ALDH1A1 (0.44) | NR4A2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL17437961 | 0.72 | SPR (0.44) | KDM4EMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL18137295 | 0.72 | NPC1 (0.49) | NR4A2KDM4EMAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012072512-A1 | N-CYCLOBUTYL-IMIDAZOPYRIDINE OR -PYRAZOLOPYRIDINE CARBOXAMIDES AS TRPV1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | WO | disclosed |
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | DONSBACH, MARTIN (DE) | 2010-07-01 | — | — | US | disclosed |
| EP-2137185-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | Gmeiner, Dr. Peter (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008113559-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | SCHWARZ PHARMA AG (DE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1972628-A1 | Indolizines and aza-analog derivatives thereof as CNS active compounds | SCHWARZ PHARMA AG (DE) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | INMT, AANAT, AZI2 | PDE4B 295/4885NR4A2 677/4885KDM4E 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.